EGFR检测在肺癌中的临床意义

(EGFR2TKI),showsevidenceofgoodtolerabilityandactivity:FinalresultsfromaphaseIstudy[J].ProcAmSocClinOncol,2000,19:3a(abstr5E).

[31]　BaselgaJ,HerbstR,LoRussoP,etal.Continuousadministrationof

ZD1839(Iressa),anoveloralepidermalgrowthfactorreceptortyro2sinekinaseinhibitor(EGFR2TKI),inpatientswithfiveselectedtu2mortypes:Evidenceofactivityandgoodtolerability[J].ProcAmSocClinOncol,2000,19:177a(abstr686).

[32]　NakagawaK,YamamotoN,KudohS,etal.AphaseIintermittent

dose2escalationtrialofZD1839(Iressa)inJapanesewithidmalignanttumours[J].ProcSClin,19:(abstr711).

[33]　Gonzalez2LarribaJ,GG,vanOosteromAT,etal.ZD1839

()incombinationwithgemcitabineinchemonaivepatients‘Iressa’

withadvancedsolidtumours:finalresultsofaPhaseItrial[J].ProcAmSocClinOncol,2002,21:95a(A376).

[34]　MillerVA,JohnsonD,HeelanRT,etal.Apilottrialdemonstratesthe

)anoralepidermalgrowthfactorreceptorsafetyofZD1839(‘Iressa’tyrosinekinaseinhibitor(EGFR2TKI),incombinationwithcarbo2platin(C)andpaclitaxel(P)inpreviouslyuntreatedadvancednon2smallcelllungcancer(NSCLC)[J].ProcAmSocClinOncol,2001:20326a(A1301).

[35]　FukuodkM,YanoS,GiacconeG,etal.FinalresultsfromaPhaseII

)forpatientswithadvancednon2small2celltrialofZD1839(‘Iressa’lungcancer(IDEAL1)[J].ProcAmSocClinOncol,2002,21:298a(A1188).

[36]　KrisMG,NataleRB,HerbstRS,etal.APhaseIItrialofZD1839

()inadvancednon2small2celllungcancer(NSCLC)patients‘Iressa’

whohadfailedplatinum2anddocetaxel2basedregimens(IDEAL2)[J].ProcAmSocClinOncol,2002,21:292a(A1166).

[37]　GonzalezG,CrombetT,CatalaM,etal.Anovelcancervaccinecom2

posedofhuman2recombinantepidermalepidermalgrowthfactorlinkedtoacarrierprotein:reportofapilotclinicaltrial[J].AnnOncol,1998,9:431-435.

[38]　DanceyJE,FreidlinB.Targetingepidermalgrowthfactorreceptor2are

wemissingthemark?[J].Lancet,2003,362(9377):62-64.

425

[39]　SpauldingDC,SpauldingBO.Epidermalgrowthfactorreceptorexpres2

sionandmeasurementinsolidtumors[J].SeminOncol,2002,29(5Suppl14):45-54.

[40]　MeyeA,FiedlerU,KunertK,etal.Growthinhibitoryeffectsof

)onhumanbladdercancercelllines[J].ProcAmZD1839(‘Iressa’AssocCancerRes,2001,42(A4320).

[41]　ML,KruytFAEJA,etal.Inhibitionoftheepider2

malinA431cellsbutnotincell].ProcAmAssocCancerRes,　MarkM.Moasser,AndreaBasso,StevenD,etal.TheTyrosineKinase

)InhibitsHER2-drivenSignalingandInhibitorZD1839(‘Iressa’SuppressestheGrowthofHER2-overexpressingTumorCells[J].CancerResearch,2001,61(October1):7184-7188.

[43]　BaileyR,KrisM,WolfM,etal.Gefitinib(‘Iressa’ZD1839)

monotherapyforpretreatedadvancednon2small2celllungcancerinIDEAL1and2:tumorresponseisnotclinicallyrelevantlypredictablefromtumorEGFRmembranestainingalone[J].LungCancer,2003,41(suppl2):S71.AbstractO-242.

[44]　MillerVA,ShahN,KrisMG.Clinical,pathologicandmole2cular

characteristicsofNSCLCpatientssensitivetogefi2tinib[J].LungCancer,2003,41(suppl2):S71.AbstractO-241.

[45]　Perez2SolerR,DaiQ,LeeM,etal,Molecularmechanismsofsensitivi2

tyandresistancetotheHER1/EGFR-tyrosinekinaseinhibitorer2lotinib(Tarceva)[J].LungCancer,2003,41(suppl2):S72.AbstractO-247.

[46]　SandlerAB,MininbergE,HendersonT,etal.AphaseI/IIstudyof

theanti2VEGFMAb,bevacizumab(Avastin)anderlo2tinib(Tarce2va),aHER1/EGFR-TKinhibitor:amulti2facetedapproachforthetreatmentofrecurrentnon2smallcelllungcancer[J].LungCancer,2003,41(suppl2):S36.AbstractO-112.

[47]　OπByrneKJ,ClarkeL,DunlopD,etal.Clinicalevaluationofgefitinib

(Iressa,ZD1839)incombinationwithrofecoxibincisplatinpre2treat2edrelapsednon2smallcelllungcancer[J].LungCancer,2003,41(suppl2):S36.AbstractO-113.

收稿日期:2003-09-19;　修回日期:2003-10-20